| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Arbor Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.59M | Series C-2 | 10/8/2025 | $26.09M | $282.07M | $4.52 | Undisclosed Investors | ||||
 | Freenome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.35B | Series F | 2/15/2024 | $263.96M | $2.05B | $7.40 | Roche, Andreessen Horowitz, BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates | ||||
 | Skyhawk Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Ajax Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | AQEMIA | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | ArteraAI | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $97.32M | Series Seed-3 | 2/1/2024 | $82.82M | $408.31M | $7.95 | Coatue, Johnson & Johnson Innovation, Koch Disruptive Technologies, Walden Catalyst, TIME Ventures, Breyer Capital, The Factory, Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, Michael Driscoll, Prosperity7 Ventures, EDBI, Wilson Sonsini Goodrich & Rosati, Trium Ventures, Navin Chaddha, Rajiv Khemani, Andrew Tan, Elliott Tan | ||||
 | BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170M | $440.23M | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | ||||
 | Egenesis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.4B | Series D | 9/4/2024 | $90.96M | $332.59M | $0.20 | Lux Capital, ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation | ||||
 | Frontier Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.5M | Series C | 6/25/2024 | $100M | $438.18M | $2.34 | Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC, MPM Capital, RA Capital Management, Deep Track Capital, ArrowMark Partners | ||||
 | Kumquat Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $135.92M | Series A-2 | 7/28/2021 | $30M | $494.98M | $10.32 | Undisclosed Investors | ||||
 | AiTA | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25.63M | Series C | 1/14/2025 | $10M | $317.19M | $5.05 | Undisclosed Investors | ||||
 | Pendulum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $121.76M | Series C | 6/30/2023 | $64M | $308.05M | $3.24 | Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, Fonterra | ||||
 | Sionna Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.32M | Series C | 3/6/2024 | $181.86M | $523.7M | $9.76 | Enavate Sciences, Viking Global Investors, Perceptive Advisors, RA Capital, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Qatar Investment Authority, OrbiMed | ||||
 | Accutar Biotechnology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $207.47M | Series B+4 | 8/20/2021 | $80M | $987.52M | $77.58 | Undisclosed Investors | ||||
 | Affinia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $219.17M | Series C | 10/7/2025 | $40M | $156.61M | $1.62 | New Enterprise Associates, Eli Lilly, Alexandria Venture Investments, Atlas Venture, Avidity Partners, F-Prime Capital, GV, Mass General Brigham Ventures, Perceptive Advisors | ||||
 | BlueRock Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Hemab Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Neurona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $342.29M | Series F | 4/3/2025 | $101.71M | $578.63M | $2.06 | Fidelity, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, Spur Capital Partners | ||||
 | Rakuten Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $874.92M | Series F-3 | 1/7/2026 | $3.6M | $636.9M | $1.03 | Taiwania Capital, Axil Capital Group, Daiwa Securities, Mitsui Sumitomo Insurance Company, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten, Mickey Mikitani | ||||
 | Ultima Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Umoja Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $373.84M | Series C | 1/14/2025 | $100M | $422.45M | $3.95 | Double Point Ventures, DCVC Bio, ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank, CaaS Capital, Emerson Collective, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota | ||||
 | Kallyope | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $479.46M | Series D | 2/15/2022 | $236M | $1.27B | $5.45 | Mubadala, The Column Group, Alexandria Venture Investments, Bill Gates, Casdin Capital, Euclidean Capital, Illumina Ventures, Lux Capital, Polaris Partners, Two Sigma Ventures, StepStone Group, DNS Capital, Hartford Healthcare Endowment, Parkwood, Tao Capital | ||||
 | Lycia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $277.05M | Series D | 6/10/2026 | $75M | $388.52M | $2.04 | Janus Henderson Investors, Balyasny Asset Management, Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly and Company, Franklin Templeton, Invus, RTW Investments, Venrock | ||||
 | Odyssey Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $413.6M | Series D | 9/10/2025 | $213.63M | $527.3M | $14.62 | Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG, Wedbush Healthcare Partners | ||||